

ABSTRACT OF THE INVENTION

This invention comprises a recombinant protein comprising the maltose binding protein (MBP) of *Escherichia coli* fused to amino acids 5-337 of the FlaA flagellin of *Campylobacter coli* VC167 which has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of *campylobacter*, *Campylobacter jejuni* 81-176 in mammals. The invention further comprises a recombinant DNA construct encoding the immunodominant region (region I through III) of flagellin from *Campylobacter* spp. for use as a component of a vaccine against *Campylobacter* diarrhea. The invention therefore represents an effective treatment against *Campylobacter* but avoids inducing the autoimmune Guillain Barre Syndrome (GBS), a post-infection polyneuropathy caused by *Campylobacter* molecular mimicry of human gangliosides which has hampered the development of vaccines heretofore.